Clinical Trial Update: A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 study evaluating induction and maintenance Rituximab (MabThera) in patients with indolent B-cell non-Hodgkin lymphoma; trial completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• MabThera (Rituximab) (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-08-21